Pregabalin Market Research Report by Dosage Forms, Drug Class, Application, End-Users, Distribution Channel, State - United States Forecast to 2027 - Cumulative Impact of COVID-19

Pregabalin Market Research Report by Dosage Forms, Drug Class, Application, End-Users, Distribution Channel, State - United States Forecast to 2027 - Cumulative Impact of COVID-19

The United States Pregabalin Market size was estimated at USD 209.79 million in 2021 and expected to reach USD 219.28 million in 2022, and is projected to grow at a CAGR 6.46% to reach USD 305.47 million by 2027.

Market Statistics:

The report provides market sizing and forecast across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.

Market Segmentation & Coverage:

This research report categorizes the Pregabalin to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Dosage Forms, the market was studied across Extended Release, Oral Capsule, Oral Solution, and Oral Tablet.

Based on Drug Class, the market was studied across Anticonvulsants and Fibromyalgia Agents.

Based on Application, the market was studied across Anxiety Disorder, Epilepsy, and Neuropathic Pain.

Based on End-Users, the market was studied across Homecare, Hospitals, Research institute, and Specialty Clinics.

Based on Distribution Channel, the market was studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.

Based on State, the market was studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:

We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Pregabalin market considering the current update on the conflict and its global response.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Pregabalin Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:

The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the United States Pregabalin Market, including Almelo Private Limited, Amneal Pharmaceuticals LLC, Aurobindo Pharma Limited, Bal Pharma Limited, Biomax Biotechnics Private Limited, Changzhou Pharmaceutical Factory, Cipla Limited, Dongbang FTL, Genesis Biotec Inc., Glenmark Pharmaceuticals Ltd., Hikal Ltd., Lupin Limited, Medley Pharmaceuticals Limited, Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Viatris Inc., ZCL Chemicals Ltd., and Zydus Group.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the United States Pregabalin Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the United States Pregabalin Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the United States Pregabalin Market?
4. What is the competitive strategic window for opportunities in the United States Pregabalin Market?
5. What are the technology trends and regulatory frameworks in the United States Pregabalin Market?
6. What is the market share of the leading vendors in the United States Pregabalin Market?
7. What modes and strategic moves are considered suitable for entering the United States Pregabalin Market?

Please Note: PDF & Excel + Online Access - 1 Year


1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.2. Restraints
5.1.3. Opportunities
5.1.4. Challenges
5.2. Cumulative Impact of COVID-19
6. Pregabalin Market, by Dosage Forms
6.1. Introduction
6.2. Extended Release
6.3. Oral Capsule
6.4. Oral Solution
6.5. Oral Tablet
7. Pregabalin Market, by Drug Class
7.1. Introduction
7.2. Anticonvulsants
7.3. Fibromyalgia Agents
8. Pregabalin Market, by Application
8.1. Introduction
8.2. Anxiety Disorder
8.3. Epilepsy
8.4. Neuropathic Pain
9. Pregabalin Market, by End-Users
9.1. Introduction
9.2. Homecare
9.3. Hospitals
9.4. Research institute
9.5. Specialty Clinics
10. Pregabalin Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacy
10.3. Online Pharmacy
10.4. Retail Pharmacy
11. California Pregabalin Market
11.1. Introduction
12. Florida Pregabalin Market
12.1. Introduction
13. Illinois Pregabalin Market
13.1. Introduction
14. New York Pregabalin Market
14.1. Introduction
15. Ohio Pregabalin Market
15.1. Introduction
16. Pennsylvania Pregabalin Market
16.1. Introduction
17. Texas Pregabalin Market
17.1. Introduction
18. Competitive Landscape
18.1. FPNV Positioning Matrix
18.1.1. Quadrants
18.1.2. Business Strategy
18.1.3. Product Satisfaction
18.2. Market Ranking Analysis, By Key Player
18.3. Market Share Analysis, By Key Player
18.4. Competitive Scenario
18.4.1. Merger & Acquisition
18.4.2. Agreement, Collaboration, & Partnership
18.4.3. New Product Launch & Enhancement
18.4.4. Investment & Funding
18.4.5. Award, Recognition, & Expansion
19. Company Usability Profiles
19.1. Almelo Private Limited
19.1.1. Business Overview
19.1.2. Key Executives
19.1.3. Product & Services
19.2. Amneal Pharmaceuticals LLC
19.2.1. Business Overview
19.2.2. Key Executives
19.2.3. Product & Services
19.3. Aurobindo Pharma Limited
19.3.1. Business Overview
19.3.2. Key Executives
19.3.3. Product & Services
19.4. Bal Pharma Limited
19.4.1. Business Overview
19.4.2. Key Executives
19.4.3. Product & Services
19.5. Biomax Biotechnics Private Limited
19.5.1. Business Overview
19.5.2. Key Executives
19.5.3. Product & Services
19.6. Changzhou Pharmaceutical Factory
19.6.1. Business Overview
19.6.2. Key Executives
19.6.3. Product & Services
19.7. Cipla Limited
19.7.1. Business Overview
19.7.2. Key Executives
19.7.3. Product & Services
19.8. Dongbang FTL
19.8.1. Business Overview
19.8.2. Key Executives
19.8.3. Product & Services
19.9. Genesis Biotec Inc.
19.9.1. Business Overview
19.9.2. Key Executives
19.9.3. Product & Services
19.10. Glenmark Pharmaceuticals Ltd.
19.10.1. Business Overview
19.10.2. Key Executives
19.10.3. Product & Services
19.11. Hikal Ltd.
19.11.1. Business Overview
19.11.2. Key Executives
19.11.3. Product & Services
19.12. Lupin Limited
19.12.1. Business Overview
19.12.2. Key Executives
19.12.3. Product & Services
19.13. Medley Pharmaceuticals Limited
19.13.1. Business Overview
19.13.2. Key Executives
19.13.3. Product & Services
19.14. Novartis AG
19.14.1. Business Overview
19.14.2. Key Executives
19.14.3. Product & Services
19.15. Pfizer Inc.
19.15.1. Business Overview
19.15.2. Key Executives
19.15.3. Product & Services
19.16. Teva Pharmaceutical Industries Ltd.
19.16.1. Business Overview
19.16.2. Key Executives
19.16.3. Product & Services
19.17. Torrent Pharmaceuticals Ltd.
19.17.1. Business Overview
19.17.2. Key Executives
19.17.3. Product & Services
19.18. Viatris Inc.
19.18.1. Business Overview
19.18.2. Key Executives
19.18.3. Product & Services
19.19. ZCL Chemicals Ltd.
19.19.1. Business Overview
19.19.2. Key Executives
19.19.3. Product & Services
19.20. Zydus Group
19.20.1. Business Overview
19.20.2. Key Executives
19.20.3. Product & Services
20. Appendix
20.1. Discussion Guide
20.2. License & Pricing
List of Figures
FIGURE 1. UNITED STATES PREGABALIN MARKET: RESEARCH PROCESS
FIGURE 2. UNITED STATES PREGABALIN MARKET SIZE, 2021 VS 2027
FIGURE 3. UNITED STATES PREGABALIN MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 4. UNITED STATES PREGABALIN MARKET SIZE, BY STATE, 2021 VS 2027 (%)
FIGURE 5. UNITED STATES PREGABALIN MARKET SIZE, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 6. UNITED STATES PREGABALIN MARKET COMPETITIVE STRATEGIC WINDOW, BY STATE, 2027
FIGURE 7. UNITED STATES PREGABALIN MARKET DYNAMICS
FIGURE 8. UNITED STATES PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2021 VS 2027 (%)
FIGURE 9. UNITED STATES PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2021 VS 2027 (USD MILLION)
FIGURE 10. UNITED STATES PREGABALIN MARKET COMPETITIVE STRATEGIC WINDOW, BY DOSAGE FORMS, 2027
FIGURE 11. UNITED STATES PREGABALIN MARKET SIZE, BY EXTENDED RELEASE, 2018-2027 (USD MILLION)
FIGURE 12. UNITED STATES PREGABALIN MARKET SIZE, BY ORAL CAPSULE, 2018-2027 (USD MILLION)
FIGURE 13. UNITED STATES PREGABALIN MARKET SIZE, BY ORAL SOLUTION, 2018-2027 (USD MILLION)
FIGURE 14. UNITED STATES PREGABALIN MARKET SIZE, BY ORAL TABLET, 2018-2027 (USD MILLION)
FIGURE 15. UNITED STATES PREGABALIN MARKET SIZE, BY DRUG CLASS, 2021 VS 2027 (%)
FIGURE 16. UNITED STATES PREGABALIN MARKET SIZE, BY DRUG CLASS, 2021 VS 2027 (USD MILLION)
FIGURE 17. UNITED STATES PREGABALIN MARKET COMPETITIVE STRATEGIC WINDOW, BY DRUG CLASS, 2027
FIGURE 18. UNITED STATES PREGABALIN MARKET SIZE, BY ANTICONVULSANTS, 2018-2027 (USD MILLION)
FIGURE 19. UNITED STATES PREGABALIN MARKET SIZE, BY FIBROMYALGIA AGENTS, 2018-2027 (USD MILLION)
FIGURE 20. UNITED STATES PREGABALIN MARKET SIZE, BY APPLICATION, 2021 VS 2027 (%)
FIGURE 21. UNITED STATES PREGABALIN MARKET SIZE, BY APPLICATION, 2021 VS 2027 (USD MILLION)
FIGURE 22. UNITED STATES PREGABALIN MARKET COMPETITIVE STRATEGIC WINDOW, BY APPLICATION, 2027
FIGURE 23. UNITED STATES PREGABALIN MARKET SIZE, BY ANXIETY DISORDER, 2018-2027 (USD MILLION)
FIGURE 24. UNITED STATES PREGABALIN MARKET SIZE, BY EPILEPSY, 2018-2027 (USD MILLION)
FIGURE 25. UNITED STATES PREGABALIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2027 (USD MILLION)
FIGURE 26. UNITED STATES PREGABALIN MARKET SIZE, BY END-USERS, 2021 VS 2027 (%)
FIGURE 27. UNITED STATES PREGABALIN MARKET SIZE, BY END-USERS, 2021 VS 2027 (USD MILLION)
FIGURE 28. UNITED STATES PREGABALIN MARKET COMPETITIVE STRATEGIC WINDOW, BY END-USERS, 2027
FIGURE 29. UNITED STATES PREGABALIN MARKET SIZE, BY HOMECARE, 2018-2027 (USD MILLION)
FIGURE 30. UNITED STATES PREGABALIN MARKET SIZE, BY HOSPITALS, 2018-2027 (USD MILLION)
FIGURE 31. UNITED STATES PREGABALIN MARKET SIZE, BY RESEARCH INSTITUTE, 2018-2027 (USD MILLION)
FIGURE 32. UNITED STATES PREGABALIN MARKET SIZE, BY SPECIALTY CLINICS, 2018-2027 (USD MILLION)
FIGURE 33. UNITED STATES PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2021 VS 2027 (%)
FIGURE 34. UNITED STATES PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2021 VS 2027 (USD MILLION)
FIGURE 35. UNITED STATES PREGABALIN MARKET COMPETITIVE STRATEGIC WINDOW, BY DISTRIBUTION CHANNEL, 2027
FIGURE 36. UNITED STATES PREGABALIN MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2027 (USD MILLION)
FIGURE 37. UNITED STATES PREGABALIN MARKET SIZE, BY ONLINE PHARMACY, 2018-2027 (USD MILLION)
FIGURE 38. UNITED STATES PREGABALIN MARKET SIZE, BY RETAIL PHARMACY, 2018-2027 (USD MILLION)
FIGURE 39. CALIFORNIA PREGABALIN MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 40. FLORIDA PREGABALIN MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 41. ILLINOIS PREGABALIN MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 42. NEW YORK PREGABALIN MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 43. OHIO PREGABALIN MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 44. PENNSYLVANIA PREGABALIN MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 45. TEXAS PREGABALIN MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 46. UNITED STATES PREGABALIN MARKET: FPNV POSITIONING MATRIX, 2021
FIGURE 47. UNITED STATES PREGABALIN MARKET SHARE, BY KEY PLAYER, 2021
FIGURE 48. UNITED STATES PREGABALIN MARKET COMPETITIVE SCENARIO, BY KEY TYPE, 2021
List of Tables
TABLE 1. UNITED STATES PREGABALIN MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018–2021
TABLE 3. UNITED STATES PREGABALIN MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 4. UNITED STATES PREGABALIN MARKET SIZE, BY STATE, 2018-2027 (USD MILLION)
TABLE 5. UNITED STATES PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2027 (USD MILLION)
TABLE 6. UNITED STATES PREGABALIN MARKET SIZE, BY EXTENDED RELEASE, 2018-2027 (USD MILLION)
TABLE 7. UNITED STATES PREGABALIN MARKET SIZE, BY EXTENDED RELEASE, BY STATE, 2018-2027 (USD MILLION)
TABLE 8. UNITED STATES PREGABALIN MARKET SIZE, BY ORAL CAPSULE, 2018-2027 (USD MILLION)
TABLE 9. UNITED STATES PREGABALIN MARKET SIZE, BY ORAL CAPSULE, BY STATE, 2018-2027 (USD MILLION)
TABLE 10. UNITED STATES PREGABALIN MARKET SIZE, BY ORAL SOLUTION, 2018-2027 (USD MILLION)
TABLE 11. UNITED STATES PREGABALIN MARKET SIZE, BY ORAL SOLUTION, BY STATE, 2018-2027 (USD MILLION)
TABLE 12. UNITED STATES PREGABALIN MARKET SIZE, BY ORAL TABLET, 2018-2027 (USD MILLION)
TABLE 13. UNITED STATES PREGABALIN MARKET SIZE, BY ORAL TABLET, BY STATE, 2018-2027 (USD MILLION)
TABLE 14. UNITED STATES PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD MILLION)
TABLE 15. UNITED STATES PREGABALIN MARKET SIZE, BY ANTICONVULSANTS, 2018-2027 (USD MILLION)
TABLE 16. UNITED STATES PREGABALIN MARKET SIZE, BY ANTICONVULSANTS, BY STATE, 2018-2027 (USD MILLION)
TABLE 17. UNITED STATES PREGABALIN MARKET SIZE, BY FIBROMYALGIA AGENTS, 2018-2027 (USD MILLION)
TABLE 18. UNITED STATES PREGABALIN MARKET SIZE, BY FIBROMYALGIA AGENTS, BY STATE, 2018-2027 (USD MILLION)
TABLE 19. UNITED STATES PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 20. UNITED STATES PREGABALIN MARKET SIZE, BY ANXIETY DISORDER, 2018-2027 (USD MILLION)
TABLE 21. UNITED STATES PREGABALIN MARKET SIZE, BY ANXIETY DISORDER, BY STATE, 2018-2027 (USD MILLION)
TABLE 22. UNITED STATES PREGABALIN MARKET SIZE, BY EPILEPSY, 2018-2027 (USD MILLION)
TABLE 23. UNITED STATES PREGABALIN MARKET SIZE, BY EPILEPSY, BY STATE, 2018-2027 (USD MILLION)
TABLE 24. UNITED STATES PREGABALIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2027 (USD MILLION)
TABLE 25. UNITED STATES PREGABALIN MARKET SIZE, BY NEUROPATHIC PAIN, BY STATE, 2018-2027 (USD MILLION)
TABLE 26. UNITED STATES PREGABALIN MARKET SIZE, BY END-USERS, 2018-2027 (USD MILLION)
TABLE 27. UNITED STATES PREGABALIN MARKET SIZE, BY HOMECARE, 2018-2027 (USD MILLION)
TABLE 28. UNITED STATES PREGABALIN MARKET SIZE, BY HOMECARE, BY STATE, 2018-2027 (USD MILLION)
TABLE 29. UNITED STATES PREGABALIN MARKET SIZE, BY HOSPITALS, 2018-2027 (USD MILLION)
TABLE 30. UNITED STATES PREGABALIN MARKET SIZE, BY HOSPITALS, BY STATE, 2018-2027 (USD MILLION)
TABLE 31. UNITED STATES PREGABALIN MARKET SIZE, BY RESEARCH INSTITUTE, 2018-2027 (USD MILLION)
TABLE 32. UNITED STATES PREGABALIN MARKET SIZE, BY RESEARCH INSTITUTE, BY STATE, 2018-2027 (USD MILLION)
TABLE 33. UNITED STATES PREGABALIN MARKET SIZE, BY SPECIALTY CLINICS, 2018-2027 (USD MILLION)
TABLE 34. UNITED STATES PREGABALIN MARKET SIZE, BY SPECIALTY CLINICS, BY STATE, 2018-2027 (USD MILLION)
TABLE 35. UNITED STATES PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 36. UNITED STATES PREGABALIN MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2027 (USD MILLION)
TABLE 37. UNITED STATES PREGABALIN MARKET SIZE, BY HOSPITAL PHARMACY, BY STATE, 2018-2027 (USD MILLION)
TABLE 38. UNITED STATES PREGABALIN MARKET SIZE, BY ONLINE PHARMACY, 2018-2027 (USD MILLION)
TABLE 39. UNITED STATES PREGABALIN MARKET SIZE, BY ONLINE PHARMACY, BY STATE, 2018-2027 (USD MILLION)
TABLE 40. UNITED STATES PREGABALIN MARKET SIZE, BY RETAIL PHARMACY, 2018-2027 (USD MILLION)
TABLE 41. UNITED STATES PREGABALIN MARKET SIZE, BY RETAIL PHARMACY, BY STATE, 2018-2027 (USD MILLION)
TABLE 42. CALIFORNIA PREGABALIN MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 43. CALIFORNIA PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2027 (USD MILLION)
TABLE 44. CALIFORNIA PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD MILLION)
TABLE 45. CALIFORNIA PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 46. CALIFORNIA PREGABALIN MARKET SIZE, BY END-USERS, 2018-2027 (USD MILLION)
TABLE 47. CALIFORNIA PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 48. FLORIDA PREGABALIN MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 49. FLORIDA PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2027 (USD MILLION)
TABLE 50. FLORIDA PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD MILLION)
TABLE 51. FLORIDA PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 52. FLORIDA PREGABALIN MARKET SIZE, BY END-USERS, 2018-2027 (USD MILLION)
TABLE 53. FLORIDA PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 54. ILLINOIS PREGABALIN MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 55. ILLINOIS PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2027 (USD MILLION)
TABLE 56. ILLINOIS PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD MILLION)
TABLE 57. ILLINOIS PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 58. ILLINOIS PREGABALIN MARKET SIZE, BY END-USERS, 2018-2027 (USD MILLION)
TABLE 59. ILLINOIS PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 60. NEW YORK PREGABALIN MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 61. NEW YORK PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2027 (USD MILLION)
TABLE 62. NEW YORK PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD MILLION)
TABLE 63. NEW YORK PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 64. NEW YORK PREGABALIN MARKET SIZE, BY END-USERS, 2018-2027 (USD MILLION)
TABLE 65. NEW YORK PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 66. OHIO PREGABALIN MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 67. OHIO PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2027 (USD MILLION)
TABLE 68. OHIO PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD MILLION)
TABLE 69. OHIO PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 70. OHIO PREGABALIN MARKET SIZE, BY END-USERS, 2018-2027 (USD MILLION)
TABLE 71. OHIO PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 72. PENNSYLVANIA PREGABALIN MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 73. PENNSYLVANIA PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2027 (USD MILLION)
TABLE 74. PENNSYLVANIA PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD MILLION)
TABLE 75. PENNSYLVANIA PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 76. PENNSYLVANIA PREGABALIN MARKET SIZE, BY END-USERS, 2018-2027 (USD MILLION)
TABLE 77. PENNSYLVANIA PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 78. TEXAS PREGABALIN MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 79. TEXAS PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2027 (USD MILLION)
TABLE 80. TEXAS PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD MILLION)
TABLE 81. TEXAS PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 82. TEXAS PREGABALIN MARKET SIZE, BY END-USERS, 2018-2027 (USD MILLION)
TABLE 83. TEXAS PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 84. UNITED STATES PREGABALIN MARKET: FPNV POSITIONING MATRIX - SCORES, 2021
TABLE 85. UNITED STATES PREGABALIN MARKET: FPNV POSITIONING MATRIX - BUSINESS STRATEGY, 2021
TABLE 86. UNITED STATES PREGABALIN MARKET: FPNV POSITIONING MATRIX - PRODUCT SATISFACTION, 2021
TABLE 87. UNITED STATES PREGABALIN MARKET RANKING, BY KEY PLAYER, 2021
TABLE 88. UNITED STATES PREGABALIN MARKET SHARE, BY KEY PLAYER, 2021
TABLE 89. UNITED STATES PREGABALIN MARKET MERGER & ACQUISITION
TABLE 90. UNITED STATES PREGABALIN MARKET AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 91. UNITED STATES PREGABALIN MARKET NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 92. UNITED STATES PREGABALIN MARKET INVESTMENT & FUNDING
TABLE 93. UNITED STATES PREGABALIN MARKET AWARD, RECOGNITION, & EXPANSION
TABLE 94. UNITED STATES PREGABALIN MARKET: LICENSE & PRICING

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings